Personalis, Inc.
| Cancer Genomics | |
| ISIN | 🆔 |
| Industry | Pharmaceutical |
| Founded 📆 | 2011 in Menlo Park, California, United States |
| Founder 👔 | |
| Headquarters 🏙️ | , Menlo Park , United States |
Area served 🗺️ | |
| Products 📟 | ImmunoID NeXT |
| Members | |
Number of employees | |
| 🌐 Website | personalis |
| 📇 Address | |
| 📞 telephone | |
Personalis, Inc. is a public American company based in Menlo Park, California focused on the development of next-generation oncological therapies by providing more comprehensive molecular data about each patient’s cancer and immune response through the use of the ImmunoID NeXT Platform, developed and marketed by Personalis.
History[edit]
Personalis Inc. was founded in 2011 by a multidisciplinary team of Stanford University researchers including:
- Russ Altman - Chair, Bioengineering
- Euan Ashley - Director, Stanford Center for Inherited Cardiovascular Disease
- Atul Butte - Chief, Division of Systems Medicine, Pediatrics
- Michael P. Snyder - Chair, Genetics; Director, Stanford Center for Genomics and Personalized Medicine[1]
The company resulted from a collaboration between the Stanford researchers and John West, Personalis’ current CEO, that looked at next generation DNA sequencing data for West, his wife, and his two children leading to a publication in PLoS Genetics in September 2011.[2]
Personalis was founded in 2011 with a $20 million Series A financing supported by Lightspeed Venture Partners and Mohr Davidow Ventures among others.[3]
Personalis launched its marquee research platform, ImmunoID NeXT, in 2019. This platform expands upon the analytics available in the previous generation by offering deeper data and enhanced analytical pipelines for key immunogenomics modules including human leukocyte antigen loss_of_heterozygosity and antigen processing machinery defects. The company has embarked on a number of collaborations and research agreements focusing on this latest platform.[4][5]
The initial public offering was completed in June 2019 and the company is listed on NASDAQ.[6]
Products[edit]
Personalis’ products support precision and personalized medicine through the use of next generation sequencing technologies and data services supporting the delivery and analysis of complex genomic data. These products and services have been designed for pharmaceutical companies to aid in the development and clinical testing of new cancer therapies including immune checkpoint modulators, personalized cancer therapies, and more traditional targeted therapies through genomic analysis of both responders and non-responders.[7]
ImmunoID NeXT[edit]
Personalis’ current generation platform is known as ImmunoID NeXT.[7] This platform combines multiple assays into one platform enabling complex analysis of limited sample quantities. The primary applications of the platform are biomarker discovery research and personalized therapy development, with a focus on oncology.[8]
References[edit]
- ↑ "With Stanford's Expertise, Personalis Plans to Focus on Clinical Interpretation of Human Genomes". GenomeWeb.
- ↑ "Augmented Reference, Haplotype Data Help Stanford Team Clinically Interpret West Family's Genomes". GenomeWeb.
- ↑ "Series A - Personalis - 2011-08-15 - Investors". Crunchbase.
- ↑ "In Brief This Week: Personalis, Todos Medical, Invivoscribe, and More". GenomeWeb.
- ↑ "Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform". GenomeWeb.
- ↑ "Personalis Prices $154.9M IPO". GenomeWeb.
- ↑ 7.0 7.1 "Personalis Highlights Use Cases for NeXT Platform as Company Seeks Greater Adoption". GenomeWeb.
- ↑ "Edited Transcript of PSNL.OQ earnings conference call or presentation 13-Nov-19 10:00pm GMT". finance.yahoo.com.
This article "Personalis, Inc." is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Personalis, Inc.. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
